Symbiotic.blue, the UK’s newest Techbio company has launched to innovate a next-generation artificial intelligence-driven ...

The US Food and Drug Administration (FDA) has approved Gilead Sciences (Nasdaq: GILD) Yeztugo (lenacapavir) - the company’s ...

Scholar Rock (Nasdaq: SRRK) has unveiled encouraging Phase II data for its experimental therapy apitegromab, showing the drug ...

The US Food and Drug Administration has approved US biotech Incyte’s (Nasdaq: INCY) Monjuvi (tafasitamab-cxix) with ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

The biopharmaceutical industry is grappling with a complex mid-year outlook in 2025, as accelerating innovation collides with ...

US biotech Actio Biosciences has raised $66 million in a series B round to support its pipeline of genetically targeted ...

Australian biotech PolyActiva has brought in seasoned pharma executive Jerry St Peter as chief executive, in a leadership ...

This office will serve as Celltrion’s central hub for UK operations and places the firm among a growing list of life sciences companies including Regeneron, Amgen, Gilead Sciences and Daiichi Sankyo ...

Caris Life Sciences shares ended trading at $28 per share on Wednesday, marking a 33% increase from its initial public offering (IPO) price of $21 per share.

US biopharma Mineralys Therapeutics has announced positive topline data from its Phase II Explore-CKD trial evaluating the ...

US pharma major AbbVie (NYSE: ABBV) today announced positive top-line results from its Phase III TEMPLE multicenter, ...